Ticker > Company >

ANG Lifesciences share price

ANG Lifesciences India Ltd.

BSE: 540694 SECTOR: Pharmaceuticals & Drugs  24.72 K   119   5

37.81
+1.80 (5.00%)
BSE: Today, 12:25 PM

Price Summary

Today's High

₹ 37.81

Today's Low

₹ 37.81

52 Week High

₹ 56.85

52 Week Low

₹ 21.03

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

49.37 Cr.

Enterprise Value

99.64 Cr.

No. of Shares

1.31 Cr.

P/E

0

P/B

0.75

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  50.56

CASH

5.5 Cr.

DEBT

55.77 Cr.

Promoter Holding

70.6 %

EPS (TTM)

₹  -6.41

Sales Growth

-36.54%

ROE

-10.64 %

ROCE

0.66%

Profit Growth

-1205.97 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-36.54%
3 Year-5.22%
5 Year1.54%

Profit Growth

1 Year-1205.96%
3 Year-206.06%
5 Year-208.89%

ROE%

1 Year-10.64%
3 Year17.4%
5 Year18.11%

ROCE %

1 Year0.66%
3 Year21.21%
5 Year21.18%

Debt/Equity

0.7235

Price to Cash Flow

-3.76

Interest Cover Ratio

0.0921

CFO/PAT (5 Yr. Avg.)

0.77528122271776

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 70.60 44.88
Mar 2025 70.60 44.88
Dec 2024 70.60 44.88
Sep 2024 70.60 44.88
Jun 2024 70.60 44.88
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 52.8362 days.

 Limitations

  • The company has shown a poor profit growth of -206.055587917096% for the Past 3 years.
  • The company has shown a poor revenue growth of -5.21664366670817% for the Past 3 years.
  • Company has low Interest coverage ratio of 0.0921.
  • Company has high debtor days of 204.7438.
  • Company has negative cash flow from operations of -13.1317.
  • The company is trading at a high EV/EBITDA of 35.1769.
  • Promoter pledging is high as 44.88%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 16.18 32.16 23.91 17.67 24.53
Total Expenditure 18.1 29.7 25.89 18.03 22.68
Operating Profit -1.93 2.46 -1.98 -0.36 1.85
Other Income 1.36 0.36 -0.03 0.75 0.17
Interest 1.67 1.87 1.71 2.05 1.61
Depreciation 1.51 1.62 1.84 1.3 1.45
Exceptional Items 0 0 0 0 0
Profit Before Tax -3.75 -0.67 -5.56 -2.96 -1.03
Tax -0.98 0.41 -1 -1.02 -0.24
Profit After Tax -2.77 -1.07 -4.57 -1.94 -0.79
Adjusted EPS (Rs) -2.12 -0.82 -3.5 -1.49 -0.6

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 126.83 154.28 348.67 207.01 131.37
Total Expenditure 114.15 138.94 283.12 195.35 121.81
Operating Profit 12.68 15.33 65.54 11.66 9.55
Other Income 0.42 0.75 0.95 9.84 0.84
Interest 3.46 3.98 8.31 10.92 9.77
Depreciation 1.23 2.24 5.12 8.52 7.75
Exceptional Items 0 0 0 0 -1.74
Profit Before Tax 8.41 9.86 53.06 2.07 -8.87
Tax 2.31 2.61 13.35 2.73 -0.22
Net Profit 6.1 7.25 39.71 -0.66 -8.65
Adjusted EPS (Rs.) 4.7 5.59 30.65 -0.51 -6.62

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 5.18 5.18 10.37 13.06 13.06
Total Reserves 29.37 36.17 73.11 72.48 64.02
Borrowings 5.25 5.93 12.01 10.06 6.97
Other N/C liabilities 3.37 2.69 19.28 10.55 7.49
Current liabilities 50.9 91.86 153.92 146.36 125.9
Total Liabilities 94.08 141.83 268.68 252.51 217.43
Assets
Net Block 21.17 21.89 82.32 78.68 53.35
Capital WIP 0 0.4 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.02 0.02 3.52 3.52 3.52
Loans & Advances 0.21 3.88 0.39 0.39 0.49
Other N/C Assets 0 3.75 0.88 1.7 1.7
Current Assets 72.67 111.89 181.57 168.21 158.37
Total Assets 94.08 141.83 268.68 252.51 217.43
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 8.41 9.86 53.06 2.07 -8.87
Adjustment 4.1 5.87 14.83 18.34 17.46
Changes in Assets & Liabilities -5.02 -26.29 -39.92 8.96 -8.32
Tax Paid -2.65 -0.63 -0.58 -3.36 -13.4
Operating Cash Flow 4.83 -11.18 27.39 26.01 -13.13
Investing Cash Flow -1.66 -7.79 -42.5 -9.35 20.02
Financing Cash Flow -3.95 18.81 15.29 -16.75 -7
Net Cash Flow -0.77 -0.16 0.17 -0.08 -0.12

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 70.60 70.60 70.60 70.60 70.60
rajesh gupta 70.41 70.41 70.41 70.41 70.41
saruchi gupta 0.19 0.19 0.19 0.19 0.19
PARTICULARS Sep 2019% Mar 2020% Sep 2020% Mar 2021% Sep 2024%
investors 28.99 28.99 28.99 28.99 29.40
rajeev sivasankara pillai... - - - - 1.03
arun bhanot - - 1.33 1.27 -
ways vinimay private limi... 8.30 7.84 6.91 5.53 -
display commercial privat... - - 1.48 - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INFOMERIC
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY22
Presentation Q2FY22
Presentation Q1FY22

Company News

ANG Lifesciences - Quaterly Results 14 Aug, 6:17 PM ANG Lifesciences - Quaterly Results 14 Aug, 6:17 PM ANG Lifesciences India informs about compliance certificate 16 Jul, 4:53 PM ANG Lifesciences India informs about trading window closure 21 Jun, 4:12 PM ANG Lifesciences informs about not applicability of large corporate entity 24 Apr, 5:03 PM ANG Lifesciences - Quaterly Results 14 Feb, 6:09 PM ANG Lifesciences India informs about trading window closure 25 Sep, 5:19 PM ANG Lifesciences - Quaterly Results 14 Aug, 6:42 PM ANG Lifesciences India informs about closure of trading window 29 Jun, 5:09 PM ANG Lifesciences - Quaterly Results 14 Feb, 6:37 PM ANG Lifesciences India informs about newspaper publication 17 Feb, 4:24 PM ANG Lifesciences - Quaterly Results 14 Aug, 5:54 PM ANG Lifesciences signs MoU with Himachal Pradesh Government 26 Mar, 9:48 AM ANG Lifesciences India informs about disclosure 26 Feb, 4:03 PM ANG Lifesciences gets nod to invest in ANG Healthcare India 24 Nov, 2:36 PM ANG Lifesciences India informs about company updates 9 Nov, 4:02 PM ANG Lifesciences to acquire 51% stake in Baddi Agro 9 Nov, 2:03 PM ANG Lifesciences India informs about updates 2 Nov, 12:48 PM ANG Lifesciences India informs about updates 13 Sep, 12:18 PM ANG Lifesciences India submits disclosure 11 Sep, 11:39 AM ANG Lifesciences India executes Asset purchase deal with Ind-Swift 18 Aug, 11:05 AM ANG Lifesciences India informs about disclosure 5 Jul, 2:58 PM ANG Lifesciences India informs about disclosure 30 Jan, 10:52 AM

ANG Lifesciences Stock Price Analysis and Quick Research Report. Is ANG Lifesciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse ANG Lifesciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). ANG Lifesciences has a PE ratio of -5.62067835234988 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. ANG Lifesciences has ROA of -3.6806% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. ANG Lifesciences has a Current ratio of 1.258.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. ANG Lifesciences has a ROE of -10.6367%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. ANG Lifesciences has a Debt to Equity ratio of 0.7235 which means that the company has low proportion of debt in its capital.

  • Sales growth: ANG Lifesciences has reported revenue growth of -36.5385% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of ANG Lifesciences for the current financial year is 7.2727314248132%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for ANG Lifesciences is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of ANG Lifesciences is Rs -6.4067. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of ANG Lifesciences in Ticker for free. Also, one can get the intrinsic value of ANG Lifesciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

ANG Lifesciences FAQs

Q1. What is ANG Lifesciences share price today?
Ans: The current share price of ANG Lifesciences is Rs 36.01.

Q2. What is the market capitalisation of ANG Lifesciences?
Ans: ANG Lifesciences has a market capitalisation of Rs 47.022891487 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of ANG Lifesciences?
Ans: The PE ratio of ANG Lifesciences is -5.62067835234988 and the P/B ratio of ANG Lifesciences is 0.712227327298224, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of ANG Lifesciences share?
Ans: The 52-week high share price of ANG Lifesciences is Rs 56.85, and the 52-week low share price of ANG Lifesciences is Rs 21.03.

Q5. Does ANG Lifesciences pay dividends?
Ans: Currently, ANG Lifesciences does not pay dividends. Dividend yield of ANG Lifesciences is around 0%.

Q6. What are the face value and book value of ANG Lifesciences shares?
Ans: The face value of ANG Lifesciences shares is Rs 10, while the book value per share of ANG Lifesciences is around Rs 50.5597. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of ANG Lifesciences?
Ans: ANG Lifesciences has a total debt of Rs 55.7662 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of ANG Lifesciences?
Ans: The ROE of ANG Lifesciences is -10.6367% and ROCE of ANG Lifesciences is 0.6634%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is ANG Lifesciences a good buy for the long term?
Ans: The ANG Lifesciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is ANG Lifesciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the ANG Lifesciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check ANG Lifesciences’s financials?
Ans: You can review ANG Lifesciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about ANG Lifesciences
X